Effect of urotensin II on apolipoprotein B 100 and apolipoprotein A-I expression in HepG2 cell line


1 Department of Biochemistry, Physiology Research Center, Kerman, Iran

2 Department of Biochemistry, Kerman University of Medical Sciences, Kerman, Iran


Background: Increased apolipoprotein B100 (apo B) and decreased apolipoprotein A-I (apo A-I) production are important risk factors in atherosclerosis. Urotensin II (UII), as the most potent vasoconstrictor in human, is related with hypertension and probably atherosclerosis. Because of the relationship between the hypertension and lipoprotein metabolism in atherosclerosis, the aim of this study was to test the effect of urotensin II on apo B and apo A-I expression in hepatic (HepG2) cell line.
Materials and Methods: HepG2 cells were treated with 10, 50, 100, and 200 nmol/L of urotensin II (n = 6). Relative apo B and apo A-I messenger RNA (mRNA) levels in conditioned media, normalized to glyceraldehyde-3-phosphate dehydrogenase, were measured with quantitative real-time polymerase chain reaction method. In addition, apo B and apo A-I levels were also estimated and compared with the controls using the western blotting method. Data were analyzed statistically by ANOVA and non-parametric tests.
Results: The apo B mRNA levels were not increased significantly following the treatment with UII. However, apo B protein levels were increased significantly after the treatment with urotensin II, especially at 100 and 200 nmol/L. The apo A-I mRNA and protein levels in conditioned media also were not significantly changed. However, there was a significant decrease in apo A-I mRNA and protein levels at 200 nM UII.
Conclusions: UII might increase apo B at protein level probably through participating factors in its synthesis and/ or stability/degradation. In addition, UII may have decreasing effect at more than 200 nM concentrations on apo A-I.


1. Pöss J, Custodis F, Werner C, Weingärtner O, Böhm M, Laufs U. Cardiovascular disease and dyslipidemia: Beyond LDL. Curr Pharm Des 2011;17:861-70.  Back to cited text no. 1
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.  Back to cited text no. 2
3. Chan L. Apolipoprotein B, the major protein component of triglyceride rich and low density lipoprotein. J Biol Chem 1992;267:25621-4.  Back to cited text no. 3
4. Von Eckardstein A. HDL- a difficult friend. Drug Discov Today 2008;5:315-24.  Back to cited text no. 4
5. Andrikoula M, McDowell IF. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment. Diabetes Obes Metab 2008;10:271-8.  Back to cited text no. 5
6. Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004;42:1355-63.  Back to cited text no. 6
7. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401:282-6.  Back to cited text no. 7
8. Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams Jr DL, et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 1999;266:174-8.  Back to cited text no. 8
9. Zhang L, Ke Y, Wang Y, Li X, Chen L. Association of urotensin II with angiographic severity of coronary artery disease. J Geriatr Cardiol 2007;4:229-32.  Back to cited text no. 9
10. Watanabe T, Suguro T, Kanome T, Sakamoto Y, Kodate S, Hagiwara T, et al. Human urotensin II accelerates foam cell formation in human monocyte derived macrophages. Hypertension 2005;46:738-44.  Back to cited text no. 10
11. Hayashi AA, Webb J, Choi J, Baker C, Lino M, Trigatti B, et al. Intestinal SR-BI is upregulated in insulin-resistant states and is associated with overproduction of intestinal apoB48-containing lipoproteins. Am J Physiol Gastrointest Liver Physiol 2011;301:326-37.  Back to cited text no. 11
12. Xu N, Ekstrom U, Nilsson-Ehle P. ACTH Decreases the Expression and Secretion of Apolipoprotein B in HepG2 Cell Cultures. J Biol Chem 2001;42:38680-4.  Back to cited text no. 12
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.  Back to cited text no. 13
14. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.  Back to cited text no. 14
15. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of protein from polyacrylamide gels to nitrocellulose sheets: Procedure and some application. Proc Natl Acad Sci USA 1979;76:4350-4.  Back to cited text no. 15
16. Olofsson SO, Boren J. Apolipoprotein B: A clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med 2005;258:395-410.  Back to cited text no. 16
17. Wilcox LJ, Barrett PH, Newton RS, Huff MW. ApoB100 Secretion from HepG2 Cells is decreased by the ACAT Inhibitor CI-1011. An effect associated with enhanced intracellular degradation of ApoB. Arterioscler Thromb Vasc Biol 1999;19:939-49.  Back to cited text no. 17
18. Pullinger CR, North JD, Teng B, Rifici VA, Ronhild de Brito AE, Scott J. The apolipoprotein B gene is constitutively expressed in HepG2 cells: Regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life. J. Lipid Res 1989;30:1065-77.  Back to cited text no. 18
19. Haas MJ, Alamir AR, Sultan S, Chehade JM, Wong NC, Mooradian AD. Nicotinic acid induces apolipoprotein A-I gene expression in HepG2 and Caco-2 cell lines. Metab Clin Exp 2011;60:1790-6.  Back to cited text no. 19
20. Li J, Chen J. Inflammation may be a bridge connecting hypertension and atherosclerosis. Med Hyp 2005;64:925-9.  Back to cited text no. 20
21. Pakala R. Role of urotensin II in atherosclerotic cardiovascular diseases. Cardiovasc Revasc Med 2008;9:166-78.  Back to cited text no. 21
22. Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B, et al. Identification of the natural ligand of an orphan G-proteincoupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1999;1:383-5.  Back to cited text no. 22
23. Richards AM, Charles C. Urotensin II in cardiovascular system. Peptides 2004;25:1795-802.  Back to cited text no. 23
24. Watanabe T, Takahashi K, Kanome T, Hongo S, Miyazaki A, Koba S, et al. Human urotensin-II potentiates the mitogenic effect of mildly oxidized low-density lipoprotein on vascular smooth muscle cells: Comparison with other vasoactive agents and hydrogen peroxide. Hypertens Res 2006;29:821-31.  Back to cited text no. 24
25. Tamura K, Okazaki M, Tamura M, Isozumi K, Tasaki H, Nakashima Y. Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: Involvement of cell adhesionmediated integrin signaling. Life Sci 2003;72:1049-60.  Back to cited text no. 25
26. Shi L, Ding W, Li D, Wang Z, Jiang H, Zhang J, et al. Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis 2006;188:260-4.  Back to cited text no. 26
27. Heringlake M, Kox T, Uzun O, Will B, Bahlmann L, Klaus S, et al. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 2004;121:129-36.  Back to cited text no. 27
28. Sauzeau V, Le Mellionec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G. Human urotensin II -induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and rhokinase. Circ Res 2001;88:1102-4.  Back to cited text no. 28
29. Parish S, Peto R, Palmer A, Clarke R, Lewington S, Offer A, et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J 2009;30:2137-46.  Back to cited text no. 29
30. Bousette N, D' Orleans-Juste P, Kiss RS, You Z, Genest J, Al-Ramli W, et al. Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype. Circ Res 2009;105:686-95.  Back to cited text no. 30
31. Kiss RS, You Z, Genest J Jr, Behm DJ, Giaid A. Urotensin II differentially regulates macrophage and hepatic cholesterol homeostasis. Peptides 2011;32:956-63.  Back to cited text no. 31
32. Wilcox LJ, Barrett PH, Huff MW. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res 1999;40:1078-89.  Back to cited text no. 32
33. Yanagita T, Han S, Hu Y, Nagao K, Kitajima H, Murakami S. Taurine reduces the secretion of apolipoprotein B100 and lipids in HepG2 cells. Lipids Health Dis 2008;7:38.  Back to cited text no. 33
34. Matsuura F, Oku H, Koseki M, Sandoval JC, Yuasa- Kawase M, Tsubakio-Yamamoto K, et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun 2007;358:1091-5.  Back to cited text no. 34
35. Oku H, Matsuura F, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, et al. Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. FEBS Lett 2007;581:5029-33.  Back to cited text no. 35
36. Lamon-Fava S. Genistein activates apolipoprotein A-I gene expression in the human hepatoma cell line HepG2. J Nutr 2000;130:2489-92.  Back to cited text no. 36
37. Qin S, Liu T, Kamanna VS, Kashyap ML. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 Cells: Involvement of PPAR-α. Arterioscler Thromb Vasc Biol 2007;27:2428-34.  Back to cited text no. 37